Pembrolizumab and atezolizumab in triple-negative breast cancer
Crossref DOI link: https://doi.org/10.1007/s00262-020-02736-z
Published Online: 2020-10-05
Published Print: 2021-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kwapisz, Dorota http://orcid.org/0000-0002-2088-2544
Text and Data Mining valid from 2020-10-05
Version of Record valid from 2020-10-05
Article History
Received: 16 June 2020
Accepted: 25 September 2020
First Online: 5 October 2020
Compliance with ethical standards
:
: Author has no conflicts of interest to declare.